Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies
Clinical trial NCT02924402 · COMPLETED
Trial details
- NCT number
- NCT02924402
- Sponsor
- Xencor, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-10-01
- Primary completion
- 2024-04-01
- Enrollment
- 154
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.